Reply to Troth et al

Shuntai Zhou¹, Collin S Hill¹, Blaide M D Woodburn^{1

2}, Raymond F Schinazi³, Ronald Swanstrom^{1

4}

Affiliations

¹ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
² Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
³ Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
⁴ Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Comment

Shuntai Zhou et al. J Infect Dis. 2021.

. 2021 Oct 28;224(8):1443-1444.

doi: 10.1093/infdis/jiab363.

Shuntai Zhou¹, Collin S Hill¹, Blaide M D Woodburn^{1

2}, Raymond F Schinazi³, Ronald Swanstrom^{1

4}

¹ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
² Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
³ Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
⁴ Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

No abstract available

Comment in

Letter to the Editor in Response to Zhou et al.
Troth S, Butterton J, DeAnda CS, Escobar P, Grobler J, Hazuda D, Painter G. Troth S, et al. J Infect Dis. 2021 Oct 28;224(8):1442-1443. doi: 10.1093/infdis/jiab362. J Infect Dis. 2021. PMID: 34251432 Free PMC article. No abstract available.

Letter to the Editor in Response to Zhou et al.
Troth S, Butterton J, DeAnda CS, Escobar P, Grobler J, Hazuda D, Painter G. Troth S, et al. J Infect Dis. 2021 Oct 28;224(8):1442-1443. doi: 10.1093/infdis/jiab362. J Infect Dis. 2021. PMID: 34251432 Free PMC article. No abstract available.

1. Zhou S, Hill CS, Sarkar S, et al. . Beta-D-N 4-hydroxycytidine (NHC) inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells [manuscript published online ahead of print 7 May 2021]. J Infect Dis 2021;224:415–9. - PMC - PubMed
1. Painter WP, Holman W, Bush JA, et al. . Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother 2021:e02428–20. - PMC - PubMed